Reuters logo
BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance
August 31, 2017 / 1:32 PM / 25 days ago

BRIEF-Amag Pharmaceuticals announces U.S. FDA filing acceptance

Aug 31 (Reuters) - Amag Pharmaceuticals Inc:

* Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia

* Amag Pharmaceuticals Inc - ‍prescription drug user fee act target action date of February 2, 2018 for feraheme​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below